62nd ERA Congress - Profs. L. Pyne, F. Fakhouri, M. Walsh, H. Mann, N. Staplin, V. Stel & J. Barratt скачать в хорошем качестве

62nd ERA Congress - Profs. L. Pyne, F. Fakhouri, M. Walsh, H. Mann, N. Staplin, V. Stel & J. Barratt

Prof. Lonnie Pyne, Prof. Michael Walsh (both Hamilton, Ontario, Canada), Prof. Natalie Staplin (Oxford, UK), Prof. Jonathan Barratt (Leicester, UK), Prof. Vianda Stel (Amsterdam, The Netherlands), Prof. Fadi Fakhouri (Lausanne, Switzerland) and Prof. Hans Mann (Munich, Germany) present their late-breakting studies from the 62nd European Renal Association (ERA) Congress, which are commented by ERA's president, Prof. Roser Torra (Barcelona, Spain), and the Local President of the 63rd ERA Congress, Prof. Kate Stevens (Glasgow, UK). 3:22 Prof. Johannes Mann The CONFIDENCE Trial: Efficacy / Safety of combining finerenone with empagliflozin in people with chronic kidney disease and type 2 diabetes 8:34 Prof. Johannes Mann Oral semaglutide and Kidney Outcomes in Type 2 Diabetes: A Prespecified Analysis of the SOUL Randomised Cardiovascular Outcomes Trial 16:18 Prof. Natalie Staplin Impact of acute eGFR dips and markers of disease severity on effects of empagliflozin on acute kidney outcome 25:04 Prof. Michael Walsh Spironolactone in patients undergoing maintenance dialysis: the ACHIEVE trial 30:02 Prof. Lonnie Pyne Mineralocorticoid receptor antagonists in patients with kidney failure receiving dialysis: an updated systematic review and meta-analysis 40:57 Prof. Vianda Stel Exploring the Margins of Survival Benefit in Deceased Donor Kidney Transplantation: An International Target Trial Emulation 53:47 Prof. Jonathan Barratt ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, and Complement Activity in IgAN Patients 1:08:09 Prof. Fadi Fakhouri Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy Dr. Mann is Professor for Nephrology at the Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, and Nephrologist in Munich, Germany. Dr. Staplin is Associate Professor and Senior Statistician at the Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford. Dr. Walsh is Associate Professor of Medicine and Health Research Methods, Evidence and Impact at the Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. Dr. Pyne is Assistant Professor at the Department of Medicine, Division of Nephrology at McMaster University, Hamilton, Ontario, Canada. Dr. Stel is Associate professor and ERA Registry Managing Director at the Department of Medical Informatics at Amsterdam UMC, Amsterdam, The Netherlands. Dr. Barratt is Professor of Renal Medicine at the Department of Cardiovascular Sciences, University of Leicester and Leicester General Hospital, Leicester, United Kingdom. Dr. Fakhouri is Head of Service of Nephrology and Hypertension at the Faculty of Biology and Medicine, University of Lausanne, Switzerland. The interview was recorded on June 11th, 2025. Moderators: Prof. Roser Torra (Barcelona, Spain), Prof. Kate Stevens (Glasgow, UK), Sara Ksiazek, Prof. Dr. Marcus Säemann (both Vienna, Austria) and Prof. Dr. Gunnar Heine (Frankfurt am Main, Germany). Articles discussed: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. N Engl J Med 2025 doi: 10.1056/NEJMoa2410659 Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N J Am Coll Cardiol 2014 doi: 10.1016/j.jacc.2013.09.056